CD5 and myeloid sarcoma: By comparing those results to DGE in CD5− CD4+ T cells from people with MS and NIND (Supplementary Fig. 3B and Supplementary Table 5), we observed that some markers were increased in people with MS in both T cell subsets, while other markers were increased specifically in the CD5+ subset (Fig. 4D).